Dozens Of States Probe Abilify Marketing
In a 10-Q form filed Tuesday with the U.S. Securities and Exchange Commission, the company disclosed the existence of the multistate investigation into its marketing of Abilify, an anti-psychotic.
In March, Bristol-Myers received a letter from the Delaware Attorney General's Office notifying it of the investigation, it said in the filing.
Bristol-Myers did not disclose details of the investigation in the...
To view the full article, register now.